ReviewVaccines2025
Identification of T-Cell Epitopes and Vaccine Development for African Swine Fever Virus.
Review in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Live-Attenuated Vaccines Against African Swine Fever: Strategies, Lessons, and Prospects.Biology · 2026Review
- Towards an Original Anti-ASFV Vaccine: Cellular Immunity Induced by Extracellular Vesicles Engineered with ASFV Proteins.Vaccines · 2026Article
- African Swine Fever: Vaccine Advancement and Major Gaps.Microorganisms · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
African swine fever virus (ASFV) has inflicted severe devastation on the global pig industry, yet a globally approved vaccine remains unavailable. Given that cellular immunity is critical for ASFV prevention, the development of vaccines based on T-cell epitopes emerges as a promising strategy to control this virus. This review synthesizes the recent advancements and challenges in the research on ASFV T-cell epitopes, while offering insights into the potential impact of novel T-cell epitope-based vaccines. Notably, only a limited number of ASFV T-cell epitopes have been experimentally identified to date, covering fewer than 20 ASFV proteins. This bottleneck is attributed to challenges such as high swine leukocyte antigen (SLA) polymorphism, suboptimal accuracy of predicting tools, and complex experimental validation procedures. Although current studies on ASFV-specific T-cell immune responses and epitope identification are insufficient to meet vaccine development needs, continuous progress in T-cell immunology research in recent years has brought this goal closer to reality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.